Last updated 2026-07-20
- Acquired by Olympus Corporation for $300M, Feb 2021
- Raised $20M Series C led by Olympus Corporation, Oct 2018
- Raised $8M Series B led by Xenia Venture Capital, Jun 2016
Total raised
$30.0M
Last: Undisclosed Round 2018-11
Stage
Acquired
Founded
2007
Headcount
5
HQ
Hadera, Israel
Sector
Health Tech & Life Sciences
About
Medi-Tate is an Israeli medical device company dedicated to improving men's healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). Its flagship product, iTind, is a temporarily implanted nitinol device designed to reshape the prostatic urethra and bladder neck to relieve symptoms of BPH. The iTind device is a minimally invasive treatment that can be performed in an outpatient setting.
Funding history · 3 rounds · $30.0M total
2018-10
C Round
$20.0M
★ Olympus Corporation
2016-06
B Round
$8.0M
★ Xenia Venture Capital★ Laborie Medical Technologies
2015-04
A Round
$2.0M
★ Xenia Venture Capital
Headcount over time
From 10 (2018-09) to 3 (2025-12) · -7 (-70%) · 27 points · source: Finder history + radar grounding
Q&A
- What is Medi-Tate's primary focus?
- Medi-Tate develops new solutions for treating diseases of the urethra and prostate, aiming to reduce symptoms and improve patients' quality of life.
- When was Medi-Tate acquired and by whom?
- Medi-Tate was acquired by Olympus Corporation in February 2021.
- What is the iTind system and its purpose?
- The iTind system is Medi-Tate's device for treating benign prostate hyperplasia (BPH). It is placed in the prostatic urethra for five days to reshape the prostate and provide a long-term therapeutic effect.
- In which markets is Medi-Tate's iTind system available?
- The iTind system is CE marked and available for sale in the European Union, Canada, Hong Kong, and Israel.
- When did Medi-Tate receive FDA De Novo classification for its iTind system?
- Medi-Tate received an FDA De Novo classification for its iTind system in April 2020.
- Who was a lead investor in Medi-Tate's November 2018 funding round?
- Olympus Corporation was an investor in Medi-Tate's November 2018 funding round.
- What was the total amount raised by Medi-Tate before its acquisition?
- Medi-Tate raised a total of $30,000,000 USD.
- Who are the co-founders of Medi-Tate?
- Ido Kilemnik is a co-founder and CEO of Medi-Tate.
Team · 1
Ido Kilemnik
Founder · Co-founder & CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2B
Highlights
1 Patents
Tags
non-surgicalminimally-invasivetherapeutic-devicesendoscopyurinary-systemurologymedical-devicespatientshospitalsclinicstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | itind.com/ |
|---|---|
| linkedin.com/company/10291149 | |
| YouTube | youtube.com/channel/UCmYD_i77oo7BhHzeoVCQz_g |
| Wikidata | wikidata.org/wiki/Q50038698 |
Identifiers & details
| Founded | 2007 |
|---|---|
| Employees (exact) | 5 |
| Status reason | Acquired by Olympus Corporation on Feb, 2021 |
| Wikidata QID | Q50038698 |
Acquisitions & public offerings
Acquired by Olympus Corporation 2021-02 $300.0M
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | itind.com |
|---|
Wikidata
| QID | Q50038698 |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513946632 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2007-02-26 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 6 — other (1), shares_capital (1), people (2), annual_report (2) |
| Registered address | האומן 17 חדרה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-23 | שינוי בתקנון |
| 2026-06-23 | שינוי בהרכב הון - מניות-שינוי סוג מניה |
| 2025-12-21 | עדכון דירקטורים-הסרת דירקטור |
| 2026-07-21 | דו~ח שנתי-הוספת דירקטור |
| 2026-07-21 | דו~ח שנתי-הוספת בעל תפקיד |
| 2026-07-20 | עדכון בעלי תפקידים |